TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is a paper indexed in ScholarIQ from OpenAlex.
How many citations does TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors have?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has 0 citations in the OpenAlex counts ScholarIQ stores.
When was TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors published?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has 2026 year in the ScholarIQ index.
What is the open-access status of TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has green oa status in the ScholarIQ index.
What is the DOI of TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
The DOI for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is on the source record.
What is the OpenAlex record for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
The OpenAlex for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is on the source record.